INMD Stock Price and Chart NASDAQ:INMD

Our research shows that these estimate changes are directly correlated with near-term stock prices. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. You are being directed check perfume batch code to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

Investors should also note any recent changes to analyst estimates for InMode. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook. High-growth stocks tend to represent the technology, healthcare, and communications sectors.

Get the InvestorsObserver App

The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel. Any recent changes to analyst estimates for InMode should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability. The Zacks Consensus EPS estimate remained stagnant within the past month.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Investors will be hoping for strength from InMode as it approaches its next earnings release. In that report, analysts expect InMode to post earnings of $0.69 per share.

Icecure Medical Ltd

Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $140.1 million, up 15.57% from the year-ago period. The technique has proven to be very useful for finding positive surprises. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Meanwhile, the Dow gained 0.22%, and the Nasdaq, a tech-heavy index, added 0.09%. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. In the latest trading session, InMode (INMD Quick QuoteINMD – Free Report) closed at $39.49, marking a +1.02% move from the previous day. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.02%. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

Prior to today’s trading, shares of the maker of cosmetic surgery devices had lost 6.14% over the past month. This has lagged the Medical sector’s gain of 1.74% and the S&P 500’s loss of 1.27% in that time. Recent stocks from this report have soared up to +178.7% in 3 months – this month’s picks could be even better.

• As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.
• In that report, analysts expect InMode to post earnings of $0.69 per share.
• Its purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
• Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days.
• The Medical – Products industry is part of the Medical sector.
• The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell).

The company was founded on November 17, 2020 and is headquartered in New York, NY. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Analyst rating

The Medical – Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 88, putting it in the top 35% of all 250+ industries. This group has a Zacks Industry Rank of 96, putting it in the top 39% of all 250+ industries. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. INMD earnings call for the period ending September 30, 2022. InMode’s platforms provide effective treatments for aesthetic conditions without requiring patients to go under a scalpel.

Shares of the aesthetics industry’s favorite medical technology provider are already up 64% over the past 12 months. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

Time to Upgrade!

Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Shares of Israeli medical technology company InMode Ltd. jumped 2% premarket after the company announced plans for a 2-for-1 stock split. The split will take place on Sept. 30 and the stock will trade on a post-split basi… Heading into today, shares of the maker of cosmetic surgery devices had lost 9.09% over the past month, lagging the Medical sector’s loss of 0.91% and the S&P 500’s loss of 1.63% in that time. This company’s minimally invasive alternative to liposuction surgery isn’t getting the attention it deserves.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. Our Quantitative Research team models direct competitors or comparable companies
from a bottom-up perspective to find companies describing their business in a
similar fashion.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. INMD’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. InMode INMD closed at $37.91 in the latest trading session, marking a -0.73% move from the prior day.

This 1 Number Shows Why InMode Stock Is a Buy

A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with https://1investing.in/ an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.

• At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
• There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
• More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
• Style is an investment factor that has a meaningful impact on investment risk and returns.
• This group has a Zacks Industry Rank of 96, putting it in the top 39% of all 250+ industries.
• Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women’s health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its products platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8.

InMode (NASDAQ: INMD)

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.72 per share and revenue of $541.1 million. These totals would mark changes of +12.4% and +19.11%, respectively, from last year. Wall Street will be looking for positivity from InMode as it approaches its next earnings report date. The company is expected to report EPS of $0.69, up 4.55% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $140.1 million, up 15.57% from the prior-year quarter. Its purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Compare
INMD’s historical performance
against its industry peers and the overall market.